Immix Accounts Payable from 2010 to 2025

IMMX Stock  USD 1.94  0.03  1.52%   
Immix Biopharma Accounts Payable yearly trend continues to be fairly stable with very little volatility. Accounts Payable is likely to outpace its year average in 2025. Accounts Payable is the amount Immix Biopharma owes to suppliers or vendors for products or services received but not yet paid for. It represents Immix Biopharma's short-term liabilities. View All Fundamentals
 
Accounts Payable  
First Reported
2010-12-31
Previous Quarter
1.6 M
Current Value
1.7 M
Quarterly Volatility
557 K
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Immix Biopharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Immix Biopharma's main balance sheet or income statement drivers, such as Tax Provision of 12.5 K, Net Interest Income of 414.7 K or Depreciation And Amortization of 6.6 K, as well as many indicators such as Dividend Yield of 0.0, Ptb Ratio of 6.91 or Book Value Per Share of 0.88. Immix financial statements analysis is a perfect complement when working with Immix Biopharma Valuation or Volatility modules.
  
Check out the analysis of Immix Biopharma Correlation against competitors.
For more information on how to buy Immix Stock please use our How to Invest in Immix Biopharma guide.

Latest Immix Biopharma's Accounts Payable Growth Pattern

Below is the plot of the Accounts Payable of Immix Biopharma over the last few years. An accounting item on the balance sheet that represents Immix Biopharma obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Immix Biopharma are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. It is the amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities. Immix Biopharma's Accounts Payable historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Immix Biopharma's overall financial position and show how it may be relating to other accounts over time.
Accounts Payable10 Years Trend
Slightly volatile
   Accounts Payable   
       Timeline  

Immix Accounts Payable Regression Statistics

Arithmetic Mean489,072
Geometric Mean328,310
Coefficient Of Variation113.89
Mean Deviation418,019
Median247,542
Standard Deviation557,007
Sample Variance310.3B
Range1.6M
R-Value0.65
Mean Square Error191.3B
R-Squared0.42
Significance0.01
Slope76,235
Total Sum of Squares4.7T

Immix Accounts Payable History

20251.7 M
20241.6 M
20231.4 M
2022143.1 K
2021142.9 K
2020252.3 K

About Immix Biopharma Financial Statements

Immix Biopharma investors use historical fundamental indicators, such as Immix Biopharma's Accounts Payable, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Immix Biopharma. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Accounts Payable1.6 M1.7 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Immix Stock Analysis

When running Immix Biopharma's price analysis, check to measure Immix Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immix Biopharma is operating at the current time. Most of Immix Biopharma's value examination focuses on studying past and present price action to predict the probability of Immix Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immix Biopharma's price. Additionally, you may evaluate how the addition of Immix Biopharma to your portfolios can decrease your overall portfolio volatility.